Compare · APT vs EW
APT vs EW
Side-by-side comparison of Alpha Pro Tech Ltd. (APT) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both APT and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $52.38B, about 957.4x APT ($54.7M).
- Both names hit the wire about 3 times in the past 4 weeks.
- EW has more recent analyst coverage (25 ratings vs 0 for APT).
- Company
- Alpha Pro Tech Ltd.
- Edwards Lifesciences Corporation
- Price
- -
- -
- Market cap
- $54.7M
- $52.38B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- AMEX
- NYSE
- IPO
- 2000
- News (4w)
- 3
- 3
- Recent ratings
- 0
- 25
Alpha Pro Tech Ltd.
Alpha Pro Tech, Ltd., together with its subsidiaries, develops, manufactures, and markets a range of disposable protective apparel, infection control, and building supply products in the United States and internationally. The company operates through two segments, Disposable Protective Apparel and Building Supply. The Disposable Protective Apparel segment provides shoe covers, bouffant caps, coveralls, frocks, lab coats, and gowns, hoods, as well as face masks and shields. The Building Supply segment offers construction weatherization products, such as housewrap, synthetic roof underlayment, and other woven materials. The company markets its products under the Alpha Pro Tech brand name, as well as under private labels. Its products are used primarily in cleanrooms; industrial safety manufacturing environments; health care facilities, such as hospitals, laboratories, and dental offices; building and re-roofing sites; and pharmaceutical markets. The company distributes its products through a network of purchasing groups, distributors, and independent sales representatives, as well as through its sales and marketing force. Alpha Pro Tech, Ltd. was founded in 1983 and is headquartered in Markham, Canada.
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest APT
- SEC Form 10-Q filed by Alpha Pro Tech Ltd.
- Alpha Pro Tech Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Alpha Pro Tech, Ltd. Announces Second Quarter 2026 Financial Results
- Alpha Pro Tech Ltd. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Garcia David R exercised 4,900 units of options at a strike of $4.23 and sold $34,421 worth of shares (6,186 units at $5.56), decreasing direct ownership by 6% to 19,768 units (SEC Form 4)
- Director Garcia David R sold $28,788 worth of shares (4,900 units at $5.88) and exercised 4,900 units of options at a strike of $3.99 (SEC Form 4)
- SEC Form 144 filed by Alpha Pro Tech Ltd.
- Director Montgomery Charles D sold $152,319 worth of shares (23,886 units at $6.38), decreasing direct ownership by 49% to 25,281 units (SEC Form 4)
- SEC Form 10-Q filed by Alpha Pro Tech Ltd.
- Alpha Pro Tech Ltd. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest EW
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,967 worth of shares (619 units at $92.03) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form S-8 filed by Edwards Lifesciences Corporation
- SEC Form 10-Q filed by Edwards Lifesciences Corporation
- CVP, JAPAC Markowitz Wayne sold $12,588 worth of shares (146 units at $86.03), decreasing direct ownership by 0.67% to 21,534 units (SEC Form 4)
- CVP, JAPAC Markowitz Wayne exercised 9,628 shares at a strike of $74.02 and sold $818,958 worth of shares (9,628 units at $85.06) (SEC Form 4)
- UBS initiated coverage on Edwards Lifesciences with a new price target
- CEO Zovighian Bernard J gifted 320 shares, received a gift of 320 shares and sold $245,134 worth of shares (2,921 units at $83.93), decreasing direct ownership by 0.32% to 98,845 units (SEC Form 4)
- Edwards Lifesciences upgraded by Leerink Partners with a new price target
- Edwards Lifesciences Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Edwards Lifesciences Reports Second Quarter Results